Experimental/Investigational uses: ADAMTS13 assay for the enumerated indications (items 1–42 in the policy) including but not limited to: biomarker roles after subarachnoid hemorrhage, COVID-19 disease severity and micro-thrombosis risk, early detection of hepatocellular carcinoma, monitoring progression of acute myocardial infarction, treatment response and prediction in HCC, risk assessment for endometriosis, diabetic retinopathy diagnosis/monitoring, sepsis-associated TMA monitoring, diagnosis of cholangitis, AML diagnosis, acute pancreatitis, arterial thrombosis, cerebral infarction, disseminated intravascular coagulation, IBD activity evaluation, HUS, perioperative assessment in type 1 VWD, ischemic complications of malignant hypertension, liver disease monitoring, pregnancy in COVID-19, post-kidney transplant renal monitoring, obstructive sleep apnea progression, prediction of AKI in COVID-19, PCI and AF outcome prediction, post-operative drainage after CABG, HCC development prediction, HBV HBeAg seroconversion prediction, recurrence and relapse predictions in multiple contexts, pre-eclampsia, melanoma prognosis, TBI prognosis, intracranial aneurysm risk, thrombosis risk in pediatric congenital heart disease, plus additional listed uses; and (separately) ADAMTS13 mutation testing for non-cirrhotic portal hypertension; and use of the VWF:Ag/ADAMTS13 activity ratio as a prognostic biomarker in acute-on-chronic liver failure.